Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand in I&I.
Biogen CEO Chris Viehbacher at the Financial Times summit in New York.
June 17, 2026 08:43 PM EDT
Deals
Biogen makes up to $1B deal for secretive anti-inflammatory biotech
Kyle LaHucik
Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease…
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of…
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in…
Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will support…
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a
